ASP:CA:TSX-Acerus Pharmaceuticals Corporation (CAD)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | TSX

Last Closing Price

CAD 0.03

Change

0.00 (0.00)%

Market Cap

CAD 0.05B

Volume

0.06M

Avg Analyst Target

N/A

Avg User Target

CAD
Average Analyst Rating

N/A

Fundamental Analysis

Verdict


Acerus Pharmaceuticals Corporation (ASP) Stock Analysis:
Based on the Acerus Pharmaceuticals Corporation stock forecasts from 0 analysts, the average analyst target price for Acerus Pharmaceuticals Corporation is not available over the next 12 months. Acerus Pharmaceuticals Corporation’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Acerus Pharmaceuticals Corporation is Very Bearish, which is based on 0 positive signals and 8 negative signals. At the last closing, Acerus Pharmaceuticals Corporation’s stock price was CAD 0.03. Acerus Pharmaceuticals Corporation’s stock price has changed by -0.01 % over the past week, -0.02 % over the past month and -16.67 % over the last year.

About

Acerus Pharmaceuticals Corporation, a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and distribution of pharmaceutical products for men's and women's health. The company offers Natesto, a nasal gel for testosterone replacement therapy in ad ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-12-07 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
BHC:CA Bausch Health Companies Inc

+0.82 (+2.64%)

CAD10.94B N/A 23.61
TLRY:CA Tilray Inc

+0.26 (+2.23%)

CAD5.43B N/A N/A
WEED:CA Canopy Growth Corporation

+0.53 (+4.09%)

CAD5.06B N/A N/A
APHA:CA Aphria Inc

N/A

CAD4.44B 57.08 598.01
CRON:CA Cronos Group Inc

+0.20 (+3.63%)

CAD1.99B 46.76 N/A
ACB:CA Aurora Cannabis Inc

+0.48 (+6.30%)

CAD1.47B 1,171.00 N/A
OGI:CA OrganiGram Holdings Inc

+0.17 (+7.17%)

CAD0.71B -99,999.99 N/A
GUD:CA Knight Therapeutics Inc

-0.01 (-0.19%)

CAD0.64B 20.88 6.94
HLS:CA HLS Therapeutics Inc

-0.12 (-0.80%)

CAD0.48B N/A 24.44
HEXO:CA HEXO Corp

+0.11 (+8.73%)

CAD0.39B N/A N/A

ETFs Containing ASP:CA

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -37.50% 40% F 6% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -37.50% 40% F 6% F
Trailing 12 Months  
Capital Gain -16.67% 60% D- 11% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -16.67% 60% D- 11% F
Trailing 5 Years  
Capital Gain -77.05% 8% F 4% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -77.05% 8% F 3% F
Average Annual (5 Year Horizon)  
Capital Gain 2.45% 44% F 35% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 2.45% 44% F 26% F
Risk Return Profile  
Volatility (Standard Deviation) 77.58% 32% F 11% F
Risk Adjusted Return 3.16% 44% F 14% F
Market Capitalization 0.05B 28% F 19% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 5.00 68% D+ 82% B-
Price/Book Ratio 18.06 6% F 3% F
Price / Cash Flow Ratio -2.08 43% F 80% B-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -2,241.97% 3% F 1% F
Return on Invested Capital -231.82% 3% F 1% F
Return on Assets -122.73% 3% F 0% N/A
Debt to Equity Ratio 208.23% 22% F 11% F
Technical Ratios  
Short Ratio 0.29 77% C+ 73% C
Short Percent 0.03% 93% A 89% B+
Beta 0.97 79% C+ 58% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector